Information  X 
Enter a valid email address

Renalytix AI PLC (RENX)

  Print      Mail a friend

Thursday 21 November, 2019

Renalytix AI PLC

Grant of Options

RNS Number : 1263U
Renalytix AI PLC
21 November 2019

Renalytix AI plc

("RenalytixAI" or the "Company")


Grant of Options


Renalytix AI plc (AIM: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announces that the Remuneration Committee agreed to issue options over a total of 50,000 ordinary shares of £0.0025 each in the capital of the Company ("Share Options").


The Share Options have been issued in line with the Company's existing share option plan to Chirag Parikh, a Director of the Company. The Share Options have been issued in addition to the existing options over ordinary shares granted to Chirag Parikh on 1 November 2018, and combined the number of ordinary shares held under option by Chirag Parikh is 130,724, representing 0.22% of the existing issued ordinary share capital of the Company.


The Share Options are exercisable in 12 equal quarterly instalments over 36 months, in line with options previously granted to the Company's Directors under the Company's existing share option plan, and at an exercise price of £2.51.



For further information, please contact:


Renalytix AI plc

James McCullough, CEO

Via Walbrook PR


Stifel (Nominated Adviser & Joint Broker)

Tel: 020 7710 7600

Alex Price / Jonathan Senior / Ben Maddison

N+1 Singer (Joint Broker)

Tel: 020 7496 3000

Aubrey Powell / George Tzimas (Corporate Finance)
Tom Salvesen
/ Mia Gardner (Corporate Broking)

Walbrook PR Limited

Tel: 020 7933 8780 or [email protected]

Paul McManus / Lianne Cawthorne

Mob: 07980 541 893 / 07584 391 303


About Kidney Disease 

Kidney disease is now recognised as a public health epidemic affecting over 850 million people globally. The Centers for Disease Control estimates there that 15% of United States adults or 37 million people currently have kidney disease. It is reported that 9 out of 10 adults with chronic kidney disease do not know they have it and 1 out of 2 people with very low kidney function who are not on dialysis do not know they have CKD1. Kidney disease is referred to as a "silent killer" because it often has no symptoms and can go undetected until a very advanced stage. Each year kidney disease kills more people than breast and prostate cancer. Every day 13 patients die in the United States while waiting for a kidney transplant.


About RenalytixAI

RenalytixAI is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company's products are being designed to make significant improvements in kidney disease diagnosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery. For more information, visit






Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them



Details of the person discharging managerial responsibilities / person closely associated







Chirag Parikh



Reason for the notification










Initial notification /Amendment



Initial Notification



Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor







RenalytixAI plc









Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted





Description of the financial instrument, type of instrument


Identification code



Ordinary shares of £0.0025 ("Ordinary Shares")







Nature of the transaction



Grant of options over ordinary shares



Price(s) and volume(s)











Aggregated information

- Aggregated volume

- Price








Date of the transaction



20 November 2019



Place of the transaction



Outside trading venue - off market


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

a d v e r t i s e m e n t